The following are the objectives of Core B at The Ohio State University (OSU): (1) Synthesize sufficient quantities of selected natural products for more extensive biological evaluation, (2) Explore structure-activity relationships (SAR) and optimize pharmacological properties of highly promising agents through systematic modification of the natural product scaffold. All new compounds synthesized in these studies will be submitted for the bioassays proposed in Projects 1 and 3 and Core A, (3) Support the structural assignment of isolated natural products through chemical synthesis and/or semi-synthetic derivatization, as necessary, (4) Develop sensitive, selective, accurate and precise assays to quantify lead compounds in in vitro and in vivo biological matrices, (5) Characterize solubility, stability and metabolic profiles of lead compounds in dosing formulations and in vitro cell and enzyme preparations to support optimal formulation and derivatization, as necessary, and (6) Produce pilot plasma concentration-time profiles and determine protein and blood cell binding in mice for early estimation of pharmacokinetic properties for select compounds prior to entry into hollow fiber assays.

Public Health Relevance

The primary goal of Core B is to support the discovery, characterization and optimization of novel anticancer agents through the synthesis, structural modification, and evaluation of pharmacokinetic properties of lead compounds discovered in Projects 1-3 that demonstrate promising biological activity.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA125066-06A1
Application #
8608731
Study Section
Special Emphasis Panel (ZCA1-RPRB-C (O1))
Project Start
2006-12-01
Project End
2019-04-30
Budget Start
2014-06-06
Budget End
2015-04-30
Support Year
6
Fiscal Year
2014
Total Cost
$135,485
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Ren, Yulin; Chen, Wei-Lun; Lantvit, Daniel D et al. (2016) Cardiac Glycoside Constituents of Streblus asper with Potential Antineoplastic Activity. J Nat Prod :
Guo, Brian; Onakpa, Monday M; Huang, Xiao-Jun et al. (2016) Di-nor- and 17-nor-pimaranes from Icacina trichantha. J Nat Prod 79:1815-21
Chen, Wei-Lun; Pan, Li; Kinghorn, A Douglas et al. (2016) Silvestrol induces early autophagy and apoptosis in human melanoma cells. BMC Cancer 16:17
Ren, Yulin; Yu, Jianhua; Kinghorn, A Douglas (2016) Development of Anticancer Agents from Plant-Derived Sesquiterpene Lactones. Curr Med Chem 23:2397-420
Muñoz Acuña, Ulyana; Carcache, Peter J Blanco; Matthew, Susan et al. (2016) New acyclic bis phenylpropanoid and neolignans, from Myristica fragrans Houtt., exhibiting PARP-1 and NF-κB inhibitory effects. Food Chem 202:269-75
Othman, Nuraqilah; Pan, Li; Mejin, Michele et al. (2016) Cyclopenta[b]benzofuran and Secodammarane Derivatives from the Stems of Aglaia stellatopilosa. J Nat Prod 79:784-91
Kinghorn, A Douglas; DE Blanco, Esperanza J Carcache; Lucas, David M et al. (2016) Discovery of Anticancer Agents of Diverse Natural Origin. Anticancer Res 36:5623-5637
Ren, Yulin; Benatrehina, P Annécie; Muñoz Acuña, Ulyana et al. (2016) Isolation of Bioactive Rotenoids and Isoflavonoids from the Fruits of Millettia caerulea. Planta Med 82:1096-104
Alali, Feras; El-Elimat, Tamam; Albataineh, Hanan et al. (2015) Cytotoxic Homoisoflavones from the Bulbs of Bellevalia eigii. J Nat Prod 78:1708-15
Zhao, Ming; Onakpa, Monday M; Santarsiero, Bernard D et al. (2015) (9βH)-Pimaranes and Derivatives from the Tuber of Icacina trichantha. J Nat Prod 78:2731-7

Showing the most recent 10 out of 113 publications